Pembrolizumab for the treatment of melanoma. - Wikidata - awgldk - TriplyDB

Pembrolizumab for the treatment of melanoma.

Pembrolizumab for the treatment of melanoma.

http://www.wikidata.org/entity/Q50957132

about

Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma - A case report.Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases

P2860

Q42329560-BEA3EA59-4E4A-4E74-8AFF-A356C5613228 Q42760058-A5A318D9-B04E-4F6B-B7C7-C6D7BCDC40AF

P2860

Pembrolizumab for the treatment of melanoma.

http://www.wikidata.org/entity/Q50957132

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Pembrolizumab for the treatment of melanoma.

@en

Pembrolizumab for the treatment of melanoma.

@nl

type

label

Pembrolizumab for the treatment of melanoma.

@en

Pembrolizumab for the treatment of melanoma.

@nl

prefLabel

Pembrolizumab for the treatment of melanoma.

@en

Pembrolizumab for the treatment of melanoma.

@nl

P1433

Q50957132-EFFA3999-FC50-4FB4-8BFE-C1B4E1C5D6D6

P1476

Q50957132-588504D5-6D5C-4530-B601-D97D2E9AA867

P2093

Q50957132-4ED4EFF4-A61C-4003-A0E6-FBA44FF50527

Q50957132-650670F8-3DA3-462A-8DEC-7DA1A5FA06D7

P2860

Q50957132-0D86D723-DC30-441E-A907-280AD1034D7E

Q50957132-0ECC1C48-0242-4E9E-81AA-0BEC9C508C45

Q50957132-0ECCB80E-9BEF-4F0F-B053-91F2FBD25211

Q50957132-0F823004-6DED-492E-8DC7-47166032D975

Q50957132-13E293E6-9F03-416B-A437-68664D1F2D09

Q50957132-156FED46-B678-41A9-987C-42E9C61C4576

Q50957132-1C67F7DD-BDA2-4539-93AD-22112078A0F6

Q50957132-1C74B9A4-E305-4EAB-BFD5-F1C1E482EE3E

Q50957132-1D93404E-7C79-4185-9B95-5191AE6FB626

Q50957132-2D47C220-21F7-4926-BFB2-4F8993BA2803

P304

Q50957132-B00FAED6-2B68-42C0-A531-0CA6F3A230D2

P31

Q50957132-9FD5346F-D5D4-409E-BF3E-3DC494BBAE04

P356

Q50957132-302EA722-A236-45AF-8C98-BDEEEA6C76EB

P407

Q50957132-3C72F84B-360B-43D0-A1E9-1F6FAF9A4959

P433

Q50957132-0862E05B-0FED-48F8-A2E4-61FDEDAB1193

P478

Q50957132-90D5E48D-61DC-4815-8488-6DF356270EF8

P577

Q50957132-60F9E0D2-9CEC-4FA6-95BD-51BBBD75A9E7

P698

Q50957132-B08F7975-51F0-4E94-A7D5-C0C1C3DA38AE

P356

17512433.2015.1061430

P1433

Expert Review of Clinical Pharmacology

P1476

Pembrolizumab for the treatment of melanoma.

@en

P2093

Catriona Mairi McNeil

http://www.w3.org/2001/XMLSchema#string

Sanjeev Srinivas Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

Tumor Immunotherapy Directed at PD-1

P304

515-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2015.1061430

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26146011

http://www.w3.org/2001/XMLSchema#string